ArticleNeoplasia (New York, N.Y.)2019
MicroRNA-130a modulates a radiosensitivity of rectal cancer by targeting SOX4.
Article in Neoplasia (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.Molecular oncology · 2026Article
- From bench to bedside: advancing our understanding of radioresistance in rectal cancer.Cancer metastasis reviews · 2026Review
- MiR-142-3p promotes radioresistance by targeting FOXO4 in colorectal cancer.Biology direct · 2026Article
- Molecular mechanism of non-coding RNAs-mediated radiosensitivity regulation in colorectal cancer.World journal of gastrointestinal oncology · 2025Review
- SOX4 enhances tumor progression and cisplatin resistance in orthotopic mouse xenograft model of head and neck squamous cell carcinoma.BMC cancer · 2025Article
- SOX4 mediates cancer-associated fibroblasts related radioresistance in hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Radioresistance in rectal cancer: can nanoparticles turn the tide?Molecular cancer · 2025Review
- Understanding the molecular mechanism responsible for developing therapeutic radiation-induced radioresistance of rectal cancer and improving the clinical outcomes of radiotherapy - A review.Cancer biology & therapy · 2024Review
- Epithelial-Mesenchymal Transition-Mediated Tumor Therapeutic Resistance.Molecules (Basel, Switzerland) · 2022Review
- Inhibition of the lncRNAMolecular therapy. Nucleic acids · 2022Article
- Review
- Circular RNA circ_0000518 promotes breast cancer progression through the microRNA-1225-3p/SRY-box transcription factor 4 pathway.Bioengineered · 2022Article
- The Roles of Non-Coding RNAs in Radiotherapy of Gastrointestinal Carcinoma.Frontiers in cell and developmental biology · 2022Review
- lncRNA PCGEM1 Regulates the Progress of Colorectal Cancer through Targeting miR-129-5p/SOX4.Disease markers · 2022Article
- Improving the prediction for the response to radiotherapy of clinical tumor samples by using combinatorial model of MicroRNA expression.Frontiers in genetics · 2022Article
- Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients.Biomarker research · 2021Review
- The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- LncRNA LINC00210 regulated radiosensitivity of osteosarcoma cells via miR-342-3p/GFRA1 axis.Journal of clinical laboratory analysis · 2020Article
- Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect.Metabolites · 2020Article
- MYC-activated lncRNA HNF1A-AS1 overexpression facilitates glioma progression via cooperating with miR-32-5p/SOX4 axis.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioresistance poses a major challenge in the treatment of advanced rectal cancer. Therefore, understanding the detailed mechanisms of radioresistance may improve patient response to irradiation and the survival rate. To identify the novel targets that modulate the radiosensitivity of rectal cancer, we performed small RNA sequencing with human rectal cancer cell lines. Through bioinformatics analysis, we selected microRNA-310a (miR-130a) as a promising candidate to elucidate radioresistance. miR-130a was dramatically upregulated in radiosensitive rectal cancer cells and overexpression of miR-130a promotes rectal cancer cell radiosensitivity. Mechanically, miR-130a reversed the epithelial-mesenchymal transition phenotype of rectal cancer cells following inhibition of cell invasion upon irradiation. Moreover, miR-130a also inhibited the repair of irradiation-induced DNA damage followed by cell death. We identified that SOX4 was a direct target of miR-130a. Overexpression of SOX4 reversed the promotion activity of miR-130a on radiosensitivity. Together, our findings suggest that miR-130a functions as a radiosensitizer in rectal cancer and reveals a potential therapeutic target and preoperative prognostic marker for radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.